Alzheimer Scotland welcomes promising early findings from tarenflurbil study

Alzheimer Scotland welcomes the recent findings from Professor Gordon Wilcock’s randomised phase II trial of tarenflurbil in patients with mild to moderate Alzheimer’s Disease, but cautions that the phase III stage will be crucial in ascertaining its true potential. The Oxford-based scientists, working with researchers across the world, found that there was a dose-related effect on measures of daily activities and function in patients with mild Alzheimer’s Disease.

Jim Jackson, Chief Executive of Alzheimer Scotland, said, "These findings are promising: the focus on anti-amyloid intervention explores new avenues in the field of research into potential treatments for Alzheimer’s Disease. However, 'potential' is the key word; phase III of the trial must be completed before the true effectiveness of tarenflurbil can be assessed."

Alzheimer Scotland’s report, The Dementia Epidemic – where Scotland is now and the challenge ahead, reveals that there are currently 58,000 – 65,000 people with dementia in Scotland, but that this will rise to 102,000 – 114,000 by 2031.